Although several studies have shown that HH/Gli1 signaling pathway is involved in regulation of chemosensitivity in a variety of organ neoplasms, including pancreatic cancers, prostate cancer, and breast caners [24–26], few studies have focused on its influence on chemosensitivity in the central nervous system neoplasm. This evidence concerns the gene GLI1 and prostate cancer.